{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "esgPopulated": false, "market": "dr_market", "longName": "IDEAYA Biosciences, Inc.", "marketState": "REGULAR", "regularMarketPrice": 19.3, "messageBoardId": "finmb_329719147", "exchange": "FRA", "shortName": "IDEAYA BIOSCIENCE  DL-,01", "exchangeTimezoneShortName": "CEST", "exchangeTimezoneName": "Europe/Berlin", "regularMarketChangePercent": -3.5000038, "gmtOffSetMilliseconds": 7200000, "fiftyTwoWeekLowChange": 10.249999, "fiftyTwoWeekLowChangePercent": 1.1325966, "fiftyTwoWeekRange": "9.05 - 20.0", "fiftyTwoWeekHighChange": -0.70000076, "fiftyTwoWeekHighChangePercent": -0.035000037, "fiftyTwoWeekLow": 9.05, "fiftyTwoWeekHigh": 20.0, "earningsTimestamp": 1683626412, "earningsTimestampStart": 1683626412, "earningsTimestampEnd": 1683626412, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.52, "epsForward": -1.52, "epsCurrentYear": -1.06, "firstTradeDateMilliseconds": 1566194400000, "priceHint": 2, "regularMarketChange": -0.70000076, "regularMarketTime": 1683871252, "regularMarketDayHigh": 19.3, "regularMarketDayRange": "19.3 - 19.3", "regularMarketDayLow": 19.3, "regularMarketVolume": 2800, "regularMarketPreviousClose": 20.0, "bid": 19.8, "ask": 19.8, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 19.3, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "priceEpsCurrentYear": -18.207548, "sharesOutstanding": 57248500, "bookValue": 7.251, "fiftyDayAverage": 14.816, "fiftyDayAverageChange": 4.4839993, "fiftyDayAverageChangePercent": 0.30264574, "twoHundredDayAverage": 14.87325, "twoHundredDayAverageChange": 4.426749, "twoHundredDayAverageChangePercent": 0.2976316, "marketCap": 1104896000, "forwardPE": -12.697368, "priceToBook": 2.6617017, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "symbol": "30J.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "7000 Shoreline Court", "address2": "Suite 350", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 443 6209", "website": "https://www.ideayabio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 103, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yujiro S. Hata", "age": 48, "title": "Co-Founder, Pres, CEO & Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 851700, "fmt": "851.7k", "longFmt": "851,700"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 9729266, "fmt": "9.73M", "longFmt": "9,729,266"}}, {"maxAge": 1, "name": "Dr. Michael A. White Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 613849, "fmt": "613.85k", "longFmt": "613,849"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Darrin M. Beaupre M.D., Ph.D.", "age": 55, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 152637, "fmt": "152.64k", "longFmt": "152,637"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jeffrey  Hager Ph.D.", "age": 57, "title": "Co -Founder", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Paul A. Stone J.D.", "age": 58, "title": "CFO & Principal Accounting Officer", "yearBorn": 1964, "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Andres Ruiz Briseno CPA", "age": 36, "title": "VP and Head of Bus. Operations & IR", "yearBorn": 1986, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Paul A. Barsanti Ph.D.", "title": "Chief Technology Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jason S. Throne Esq., J.D.", "age": 50, "title": "Chief Legal Officer & Company Sec.", "yearBorn": 1972, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matthew  Maurer M.D.", "title": "VP and Head of Medical Affairs & Clinical Oncology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mick  O'Quigley", "title": "Sr. VP of Devel. Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}